Table 2

Approach-Related Complications: Food and Drug Administration Investigational Device Exemption Study of the Charité Artificial Disc

Investigational GroupControl GroupP
(N = 205)(N = 99)
All approach related, no. (%)20 (9.8)10 (10.1).925
Venous injury, no. (%)9 (4.4)2 (2.0)
Retrograde ejaculation, no. (%)a3 (3.3)3 (5.5).515
Ileus, no. (%)2 (1.0)1 (1.0)
Perioperative vein thrombosis, no. (%)2 (1.0)0
Clinically significant blood loss >1500 mL, no. (%)1 (0.5)2 (2.0)
Incisional hernia, no. (%)1 (0.5)2 (2.0)
Epidural hematoma, no. (%)1 (0.5)0
Dural tear, no. (%)1 (0.5)0
Deep vein thrombosis, no. (%)00
Arterial thrombosis, no. (%)00
  • Note. Fisher's exact test was used to test categorical variables.

  • a Of 92 men in the investigational group and 55 men in the control group.